5415.5000 -10.50 (-0.19%)
NSE Aug 25, 2025 15:31 PM
Volume: 142.3K
 

5415.50
-0.19%
Motilal Oswal
It had a positive impact of higher offtake of COVID-19 associated drugs in the recent past. The reduction in COVID-19 cases, coinciding with seasonal change, bodes well for a pick-up in the performance of Acute therapies. Bunched-up ANDA launches over the next 12-15 months are expected to improve sales growth as well as profitability of the US business. We have tweaked our FY22E/FY23E EPS estimate by 2%/3% and continue to value ALKEM at 23x 12-months forward earnings to arrive at our TP of INR3,730. We remain positive on the back of robust growth in the DF segment and...
Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.
More from Alkem Laboratories Ltd.
Recommended